UBS is not buying the excitement around Unilever PLC's (LSE:ULVR) soon-to-list ice cream business, The Magnum Ice Cream Company (TMICC).
The bank has a sell rating on the stock ahead of its debut on Monday, December 8, with a 12-month price target of 4,120p against a quoted price of 4,552p.
Its analysts think investors may be getting a little carried away with a company that still needs to prove it can grow consistently once it is out on its own.
TMICC set out its stall at a capital markets day in September. Management is chasing organic sales growth of 3–5 percent a year and aiming for 40–60 basis points of extra margin annually.
The pitch is that the business was underserved inside Unilever and can do better with clearer priorities and more investment.
UBS thinks the bigger questions sit on the demand side. Ice cream consumption per head is falling in several developed markets, including the United States, which accounts for more than a quarter of TMICC’s turnover.
The spread of weight-loss drugs is adding another wrinkle. Survey work by the bank suggests around 60% of US patients on GLP-1 medicines have cut back on ice cream. That may not derail the category, but it does create an extra headwind for a company hoping to grow faster than the market.
TMICC has been gaining market share and UBS expects it to keep outperforming, though not at the pace seen in 2024. The bank is unsure whether the group can hit its top-line targets in 2026, saying the results may be mixed.
One potential offset is a planned expansion of freezer cabinets, the branded units that retailers place in-store.
More cabinets mean better visibility and, in theory, more sales. UBS estimates this could add up to one percentage point to organic growth.
Margins are the second major battleground. Investors will want to know how quickly TMICC can close the gap with Froneri, the Nestlé-backed group that is often used as a benchmark.
UBS thinks a return to peak margins is possible, but warns that any improvement is likely to be lumpy and pushed into the late 2020s rather than delivered smoothly year after year.
Cash flow is another area where patience may be needed. The costs of separating from Unilever, combined with a ramp-up in capital spending, mean free cash flow will take time to settle.
UBS reckons the company can reach its ambitions for 2028–29, but investors should not expect a straight line from here.
Valuation is tricky, too. TMICC sits awkwardly between different peer groups: frozen foods, snacking, packaged goods and Froneri itself.
Depending on which comparison you choose, the shares could command anything from eight to 12 times expected 2026 earnings before interest, tax, depreciation and amortisation. UBS leans towards the packaged food group as the most sensible yardstick.
There are some clear risks. Turkey, which makes up 8 percent of sales, has delivered roughly half of TMICC’s organic growth over the past two and a half years, leaving the group exposed if that market slows. Consumer health trends, the shift towards more expensive “premium” treats and the sheer operational task of rolling out more freezer cabinets all add further uncertainty.
For now, UBS sees too many questions and not enough clear answers. Investors will not have long to wait before the market offers its own verdict.